Srinivas Akkaraju - 27 Feb 2024 Form 4 Insider Report for vTv Therapeutics Inc. (VTVT)

Signature
/s/ Srinivas Akkaraju
Issuer symbol
VTVT
Transactions as of
27 Feb 2024
Net transactions value
+$12,491,662
Form type
4
Filing time
29 Feb 2024, 19:33:01 UTC
Previous filing
29 Feb 2024
Next filing
06 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTVT Class A Common Stock Award $2,654,085 +224,732 +550% $11.81 265,620 27 Feb 2024 By Samsara BioCapital, L.P. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTVT Pre- Funded Warrants (Right to Buy) Award $9,837,577 +833,693 $11.80 833,693 27 Feb 2024 Class A Common Stock 833,693 $0.0100 Samsara BioCapital, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F2 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.